Minoxidil vs Finasteride: Which Works Better?

Minoxidil vs finasteride has no universal winner. For men with confirmed pattern hair loss, oral finasteride has the stronger case for slowing DHT-driven loss. Topical minoxidil suits men or women who want a nonprescription option and can manage scalp application. Two direct trials in men favored finasteride. One was open, and the larger report does not describe blinding. Diagnosis, pregnancy potential, side effects and adherence can change the answer.

This comparison means topical minoxidil versus oral finasteride for androgenetic alopecia. Oral minoxidil and topical finasteride are different prescription decisions. If tablets are what you mean, read how oral and topical minoxidil differ.

The choice in one table

Access status below was checked on 5 November 2026. Labels vary by country, sex and formulation, so the packet and local prescriber remain decisive.

Topical minoxidil versus oral finasteride for pattern hair loss

Decision	Topical minoxidil	Oral finasteride
Best fit	Men or women with diagnosed pattern hair loss who accept regular scalp application	Men with diagnosed male pattern hair loss who accept a prescription and systemic risks
What it targets	Stimulates hair growth through a different pathway; it does not block DHT	Blocks type II 5-alpha-reductase, lowering DHT that drives follicle miniaturisation in male pattern loss
Access	Over the counter in the US; General Sales List products exist in the UK	Prescription-only in both the US and UK
Earliest label window	About 2 to 4 months for early signs; a fair visual assessment often takes longer	About 3 to 6 months for early benefit or stabilisation; trials assess longer periods
Main tradeoff	Scalp irritation, unwanted facial hair and the burden of topical use	Sexual, mood and fertility concerns, plus effects on prostate-specific antigen testing
Pregnancy warning	US and UK labels warn against use during pregnancy; the UK label also excludes lactation	Contraindicated in pregnancy and not indicated for women; anyone pregnant or potentially pregnant must not handle crushed or broken tablets

Calling minoxidil a regrowth drug and finasteride a prevention drug is too neat. Both can raise hair counts and slow visible loss. The clearer difference is mechanism, access and risk.

What the direct trials found

Yes, researchers have compared the two directly. Hu and colleagues reported a 2015 randomized study of 450 Chinese men. They assigned oral finasteride, 5% topical minoxidil or both for 12 months. Among 428 men evaluated at the end, 80.5% improved with finasteride, 59.0% with minoxidil and 94.1% with the combination.

Those numbers are not your personal odds. The public report does not describe blinding or a placebo group, and “improvement” is a broad outcome. The participants were all men treated at one Chinese hospital.

Arca and colleagues ran a smaller open randomized trial in 2004. It included 65 men for 12 months. Increased hair intensity was recorded in 32 of 40 men using finasteride and 13 of 25 using minoxidil. The open design, small sample and uneven groups limit confidence in the size of that difference.

A 2022 network meta-analysis by Gupta and colleagues combined 23 studies of men. At 48 weeks, its estimate favored oral finasteride over 5% topical minoxidil by 26.2 terminal hairs per cm². The 95% credible interval was 16.2 to 36.2 hairs per cm², but the authors rated the evidence low. This was a network comparison across studies, not another head-to-head trial. Scalp regions and measurement methods also differed.

Both options beat placebo in separate studies

Separate placebo trials show that both treatments can work. They do not tell you which drug wins head to head.

Kaufman and colleagues studied 1,553 men in two one-year finasteride trials. In a 5.1 cm² vertex target area, the advantage over placebo reached 107 hairs at one year. Among 1,215 men who continued blinded treatment, the gap reached 138 hairs at two years.

Olsen and colleagues randomized 393 men to 5% minoxidil, 2% minoxidil or vehicle for 48 weeks. The 5% solution beat vehicle on hair count and both patient and investigator assessments. It produced 45% more regrowth than the 2% solution at week 48. That is a comparison between minoxidil strengths, not against finasteride.

For women, Lucky and colleagues randomized 381 participants to 5% minoxidil, 2% minoxidil or vehicle for 48 weeks. The 5% solution beat vehicle on all three main outcomes. Finasteride was not part of that trial.

How long results take

The US finasteride label says benefit generally needs at least three months. The current UK label puts early stabilisation at about three to six months. The placebo trials measured the clearer differences at one and two years.

US topical minoxidil labels allow for early results after about two months, while some people need at least four. British Association of Dermatologists guidance says visible benefit can take six to 12 months. Early change and a fair final assessment are not the same thing. This minoxidil evidence timeline explains why an eight-week mirror check can mislead.

Minoxidil can also trigger extra shedding during the first four to six weeks, according to the British guidance. That does not prove success, but it is not automatic treatment failure either.

Both treatments lose benefit after use ends. Finasteride labels say its effect reverses over roughly six to 12 months. Any prescription change belongs with the prescriber; this guide explains what studies observed after finasteride ended.

Side effects may decide the comparison

Topical minoxidil commonly causes itching, dryness, scaling or redness. Unwanted facial hair can occur if it transfers beyond the scalp. US labels tell users to stop and ask a doctor about chest pain, rapid heartbeat, faintness, dizziness, sudden weight gain or swollen hands or feet.

In the finasteride registration trials, decreased libido occurred in 1.8% of treated men and 1.3% on placebo. Erectile dysfunction occurred in 1.3% and 0.7%, while ejaculation disorder occurred in 1.2% and 0.7%. Small average differences do not rule out a serious problem for an individual.

The UK MHRA warned in 2024 about reports of depression, suicidal thoughts and sexual dysfunction that sometimes persisted after treatment. Spontaneous reports cannot establish how often persistence occurs or prove the drug caused every case. New mood symptoms or sexual problems need prompt medical contact. The prescriber should decide whether treatment changes.

Finasteride also lowers prostate-specific antigen. Anyone having a PSA test should tell the clinician about current use so the result is interpreted correctly.

Pregnancy changes the choice. US and UK finasteride labels contraindicate use in pregnancy and warn against handling crushed or broken tablets. A US women’s minoxidil label says use may be harmful during pregnancy or breastfeeding. The UK women’s foam label says it should not be used during pregnancy or lactation.

How to make the decision

1. Confirm the pattern first. Gradual crown or frontal thinning may fit androgenetic alopecia. Sudden, patchy or unexplained loss may not.
2. Separate efficacy from access. Finasteride needs a prescription. Topical minoxidil is easier to obtain, but regular scalp use can be hard to sustain.
3. Put the risk you care about on the table. Scalp irritation and unwanted hair point one way. Sexual, mood, fertility or PSA concerns point another.
4. Agree on a review point and comparable photos. Use the same lighting, distance, angle and hair part each time.

If the front edge is your concern, a photo-based hairline check with consistent framing can record its visible outline. It cannot diagnose androgenetic alopecia or prove that a treatment worked.

In the US and UK, finasteride is a prescriber decision. A clinician should also assess sudden or patchy loss, a red or painful scalp, scarring, loss after childbirth, or an unknown cause. Bring your timeline, medication list, family pattern and consistent photos. That visit should establish the diagnosis before either option is judged.